Outcome of Acute Prosthetic Joint Infections Due to Gram-Negative Bacilli Treated with Open Debridement and Retention of the Prosthesis

ABSTRACT The aim of our study was to evaluate the outcome of acute prosthetic joint infections (PJIs) due to gram-negative bacilli (GNB) treated without implant removal. Patients with an acute PJI due to GNB diagnosed from 2000 to 2007 were prospectively registered. Demographics, comorbidity, type of implant, microbiology data, surgical treatment, antimicrobial therapy, and outcome were recorded. Classification and regression tree analysis, the Kaplan-Meier survival method, and the Cox regression model were applied. Forty-seven patients were included. The mean age was 70.7 years, and there were 15 hip prostheses and 32 knee prostheses. The median number of days from the time of arthroplasty was 20. The most frequent pathogens were members of the Enterobacteriaceae family in 41 cases and Pseudomonas spp. in 20 cases. Among the Enterobacteriaceae, 14 were resistant to ciprofloxacin, while all Pseudomonas aeruginosa isolates were susceptible to ciprofloxacin. The median durations of intravenous and oral antibiotic treatment were 14 and 64 days, respectively. A total of 35 (74.5%) patients were in remission after a median follow-up of 463 days (interquartile range, 344 to 704) days. By use of the Kaplan-Meier survival curve, a C-reactive protein (CRP) concentration of ≤15 mg/dl (P = 0.03) and receipt of a fluoroquinolone, when all GNB isolated were susceptible (P = 0.0009), were associated with a better outcome. By use of a Cox regression model, a CRP concentration of ≤15 mg/dl (odds ratio [OR], 3.57; 95% confidence interval [CI], 1.05 to 12.5; P = 0.043) and receipt of a fluoroquinolone (OR, 9.09; 95% CI, 1.96 to 50; P = 0.005) were independently associated with better outcomes. Open debridement without removal of the implant had a success rate of 74.5%, and the factors associated with good prognosis were a CRP concentration at the time of diagnosis ≤15 mg/dl and treatment with a fluoroquinolone.

[1]  Á. Soriano,et al.  Timing of antibiotic prophylaxis for primary total knee arthroplasty performed during ischemia. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  E. Moran,et al.  Guiding empirical antibiotic therapy in orthopaedics: The microbiology of prosthetic joint infection managed by debridement, irrigation and prosthesis retention. , 2007, The Journal of infection.

[3]  I. Raad,et al.  Comparative Activities of Daptomycin, Linezolid, and Tigecycline against Catheter-Related Methicillin-Resistant Staphylococcus Bacteremic Isolates Embedded in Biofilm , 2007, Antimicrobial Agents and Chemotherapy.

[4]  B. Trautner,et al.  Combination of Tigecycline and N-Acetylcysteine Reduces Biofilm-Embedded Bacteria on Vascular Catheters , 2007, Antimicrobial Agents and Chemotherapy.

[5]  L. Aguilar,et al.  Conservative treatment of staphylococcal prosthetic joint infections in elderly patients. , 2006, The American journal of medicine.

[6]  Y. Yazdanpanah,et al.  Treatment of bone and joint infections caused by Gram-negative bacilli with a cefepime-fluoroquinolone combination. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[7]  Á. Soriano,et al.  Treatment of acute post-surgical infection of joint arthroplasty. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[8]  W. Zimmerli,et al.  Outcome of prosthetic knee-associated infection: evaluation of 40 consecutive episodes at a single centre. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[9]  R. Wenzel,et al.  The antibiotic pipeline--challenges, costs, and values. , 2004, The New England journal of medicine.

[10]  W. Zimmerli,et al.  Management of Infection Associated with Total Hip Arthroplasty according to a Treatment Algorithm , 2004, Infection.

[11]  T. Rimmele,et al.  Diffusion of levofloxacin into bone and synovial tissues. , 2004, The Journal of antimicrobial chemotherapy.

[12]  P. Bradford,et al.  In Vitro Activity of Tigecycline against Staphylococcus epidermidis Growing in an Adherent-Cell Biofilm Model , 2003, Antimicrobial Agents and Chemotherapy.

[13]  Robin Patel,et al.  Culture with BACTEC Peds Plus/F Bottle Compared with Conventional Methods for Detection of Bacteria in Synovial Fluid , 2001, Journal of Clinical Microbiology.

[14]  M. Sugai,et al.  Effect of the Growth Rate of Pseudomonas aeruginosa Biofilms on the Susceptibility to Antimicrobial Agents: β-Lactams and Fluoroquinolones , 1999, Chemotherapy.

[15]  P E Ochsner,et al.  Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. , 1998, JAMA.

[16]  M Drancourt,et al.  Treatment of Pseudomonas aeruginosa-infected orthopedic prostheses with ceftazidime-ciprofloxacin antibiotic combination , 1995, Antimicrobial agents and chemotherapy.